Jörg C. Mahlich : Citation Profile


Are you Jörg C. Mahlich?

Universität Wien

3

H index

1

i10 index

64

Citations

RESEARCH PRODUCTION:

19

Articles

3

Papers

1

Books

3

Chapters

EDITOR:

2

Books edited

RESEARCH ACTIVITY:

   21 years (2001 - 2022). See details.
   Cites by year: 3
   Journals where Jörg C. Mahlich has often published
   Relations with other researchers
   Recent citing documents: 1.    Total self citations: 5 (7.25 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pma997
   Updated: 2024-01-16    RAS profile: 2022-07-13    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Jörg C. Mahlich.

Is cited by:

Agarwal, Ruchir (4)

Gaulé, Patrick (4)

Rake, Bastian (3)

Managi, Shunsuke (2)

Yagi, Michiyuki (2)

Leydesdorff, Loet (2)

Goh, Kim-Leng (2)

Kuzmin, Gleb (2)

Hemmert, Martin (2)

Miraldo, Marisa (1)

Salies, Evens (1)

Cites to:

Cockburn, Iain (6)

Hall, Bronwyn (6)

Roediger-Schluga, Thomas (6)

Taylor, Alan (4)

Taylor, Mark (4)

Mueller, Dennis (4)

Henderson, Rebecca (4)

Riccaboni, Massimo (3)

Acemoglu, Daron (3)

Égert, Balázs (3)

Kawaura, Akihiko (3)

Main data


Where Jörg C. Mahlich has published?


Journals with more than one article published# docs
Health Economics Review4
Applied Health Economics and Health Policy2
PLOS ONE2
PharmacoEconomics - Open2

Recent works citing Jörg C. Mahlich (2024 and 2023)


YearTitle of citing document
2023R&D subsidies and Portuguese firms’ performance: A longitudinal firm-level study. (2023). Santos, Lus ; Teixeira, Aurora. In: GEE Papers. RePEc:mde:wpaper:0173.

Full description at Econpapers || Download paper

Jörg C. Mahlich has edited the books:


YearTitleTypeCited

Works by Jörg C. Mahlich:


YearTitleTypeCited
2016Determinants of physicians office visits and potential effects of co-payments: evidence from Austria In: International Journal of Health Planning and Management.
[Full Text][Citation analysis]
article1
2015Vergleichbarkeit internationaler Arzneimittelpreise In: Perspektiven der Wirtschaftspolitik.
[Full Text][Citation analysis]
article1
2014Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG.(2014) In: DICE Ordnungspolitische Perspektiven.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 1
paper
2010Patents and performance in the Japanese pharmaceutical industry: An institution-based view In: Asia Pacific Journal of Management.
[Full Text][Citation analysis]
article9
2006The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan In: Review of Industrial Organization.
[Full Text][Citation analysis]
article18
2006The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan.(2006) In: MERIT Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 18
paper
2005Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie In: Zeitschrift für Wirtschaftspolitik.
[Full Text][Citation analysis]
article0
2011Intangibles Kapital und Rentabilität in der Pharmaindustrie In: Die Unternehmung - Swiss Journal of Business Research and Practice.
[Full Text][Citation analysis]
article1
2018Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data In: PLOS ONE.
[Full Text][Citation analysis]
article0
2020Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study In: PLOS ONE.
[Full Text][Citation analysis]
article0
2013Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article2
2013Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]
article2
2022Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study In: Applied Research in Quality of Life.
[Full Text][Citation analysis]
article0
2022Telemedicine in Japan: Challenges and Opportunities In: Contributions to Economics.
[Citation analysis]
chapter0
2021Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis In: Health Economics Review.
[Full Text][Citation analysis]
article0
2012Economic burden of osteoporotic fractures in Austria In: Health Economics Review.
[Full Text][Citation analysis]
article1
2013Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment In: Health Economics Review.
[Full Text][Citation analysis]
article0
2014Pharmaceutical regulation in Europe and its impact on corporate R&D In: Health Economics Review.
[Full Text][Citation analysis]
article3
2017Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
article0
2019Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
article0
2007Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation In: Springer Books.
[Citation analysis]
chapter3
2007The Technological Competencies of Korea’s Firms: A Patent Analysis In: Springer Books.
[Citation analysis]
chapter1
2001The Changing Nature of Pharmaceutical R&D - Opportunities for Asia? In: Research Memorandum.
[Full Text][Citation analysis]
paper1
2019Returns on different types of investment in the global pharmaceutical industry In: Managerial and Decision Economics.
[Full Text][Citation analysis]
article1
2011R&D MANAGEMENT OF JAPANESE PHARMACEUTICAL FIRMS In: International Journal of Innovation and Technology Management (IJITM).
[Full Text][Citation analysis]
article0
2006Das D-A-CH-Reformbarometer: Reformpolitik in Deutschland, Österreich und der Schweiz In: IW-Analysen.
[Full Text][Citation analysis]
book1

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 10 2023. Contact: CitEc Team